GW Pharmaceuticals PLC- (NASDAQ:GWPH) traded down 1.6% during trading on Thursday . The company traded as low as $81.20 and last traded at $81.20, with a volume of 114,511 shares changing hands. The stock had previously closed at $82.53.

A number of equities research analysts have commented on the company. Piper Jaffray Cos. reissued a “buy” rating and set a $147.00 price target on shares of GW Pharmaceuticals PLC- in a report on Sunday, June 26th. Vetr raised GW Pharmaceuticals PLC- from a “buy” rating to a “strong-buy” rating and set a $87.65 price target on the stock in a report on Thursday, May 5th. Cowen and Company reissued a “buy” rating and set a $135.00 price target on shares of GW Pharmaceuticals PLC- in a report on Monday, June 27th. Leerink Swann reissued an “outperform” rating and set a $130.00 price target on shares of GW Pharmaceuticals PLC- in a report on Thursday, May 5th. Finally, Zacks Investment Research raised GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $108.00 price target on the stock in a report on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $126.01.

The company’s market capitalization is $1.79 billion. The company has a 50-day moving average of $90.23 and a 200-day moving average of $78.37.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.21) by $1.15. The business earned $3.10 million during the quarter, compared to analyst estimates of $3.63 million. During the same quarter in the previous year, the company posted ($0.09) EPS. The firm’s revenue was down 73.3% on a year-over-year basis. Equities research analysts expect that GW Pharmaceuticals PLC- will post ($4.52) EPS for the current year.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.